4/A//SEC Filing
Matheis Dennis 4/A
Accession 0001062993-25-010245
CIK 0001799011other
Filed
May 22, 8:00 PM ET
Accepted
May 23, 4:14 PM ET
Size
9.0 KB
Accession
0001062993-25-010245
Insider Transaction Report
Form 4/AAmended
Matheis Dennis
Director
Transactions
- Purchase
Common Stock
2025-05-20$1.29/sh+187,098$242,292→ 402,541 total - Purchase
Common Stock
2025-05-22$1.32/sh+33,218$43,795→ 565,443 total - Purchase
Common Stock
2025-05-21$1.32/sh+129,684$171,520→ 532,225 total
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.265 to $1.30. inclusive. The reporting person undertakes to provide to Lucid Diagnostics Inc., any security holder of Lucid Diagnostics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.315 to $1.32, inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.305 to $1.32, inclusive.
- [F4]Includes 52,718 shares of Lucid common stock distributed on a pro rata basis to the reporting person by a limited partnership of which the reporting person is a limited partner.
Issuer
Lucid Diagnostics Inc.
CIK 0001799011
Entity typeother
Related Parties
1- filerCIK 0001817012
Filing Metadata
- Form type
- 4/A
- Filed
- May 22, 8:00 PM ET
- Accepted
- May 23, 4:14 PM ET
- Size
- 9.0 KB